ANTICOR

The project proposes a new strategy for the screening of drugs and antibodies against the SARS-CoV-2 coronavirus. This is an innovative technology for drug screening that uses an affordable, fast, safe and efficient system to evaluate all types of antiviral compounds and antibodies that block the entry of SARS-CoV-2 virus into human cells. The use of recombinant viruses has been successfully used in drug screening for various medically important viruses, as well as in serological screening. The advantages of the proposal are well founded, highlighting that this technology may be applicable in the future to other viruses that constitute an emerging public health problem.

Description

Title: High performance platform for the screening of antiviral and SARS-CoV-2 antibodies

Research group: Viral Biology

The project proposes a new strategy for the screening of drugs and antibodies against the SARS-CoV-2 coronavirus. This is an innovative technology for drug screening that uses an affordable, fast, safe and efficient system to evaluate all types of antiviral compounds and antibodies that block the entry of SARS-CoV-2 virus into human cells. The use of recombinant viruses has been successfully used in drug screening for various medically important viruses, as well as in serological screening. The advantages of the proposal are well founded, highlighting that this technology may be applicable in the future to other viruses that constitute an emerging public health problem.

Total amount: 160.000 €

Non-UV principal researchers

Ron Geller

Start date

2020 February

End date

2020 December

Funding agencies:

Generalitat Valenciana, PTI Salut Global del CSIC